Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

FDA Expands Approval of Bosutinib for Chronic Myeloid Leukemia

The U.S. Food and Drug Administration (FDA) expanded the approval of bosutinib – an oral, once-daily tyrosine kinase inhibitor – to include adult patients...

No Survival Benefit With Adding Rituximab to Ibrutinib in Patients With Chronic Lymphocytic Leukemia

In a randomized, open-label, single-center, phase II study, researchers found that the addition of rituximab to ibrutinib did not improve progression-free survival (PFS; primary...

FDA Expands Approval of Dasatinib for Pediatric Patients With CP-CML

The U.S. Food and Drug Administration expanded the indication of the tyrosine kinase inhibitor dasatinib to include pediatric patients with Philadelphia chromosome–positive (Ph+) chronic-phase...

How I Treat In Brief: Atypical Chronic Myeloid Leukemia

This month, Jason Gotlib, MD, discusses the diagnosis and treatment of patients with atypical chronic myeloid leukemia. This material was repurposed from “How I Treat...
WIB_icon

Selinexor Induces Response in Patients With Various Subtypes of Non-Hodgkin Lymphoma and Chronic Lymphocytic...

The heterogeneity of the various subtypes of non-Hodgkin lymphomas (NHLs) necessitates the development of specific therapies that address fundamental mechanisms that are dysregulated in...

BFORE Trial: Bosutinib Could Be a “Welcome” New Treatment Option for Chronic-Phase CML

Treatment with the dual SRC/ABL tyrosine kinase inhibitor bosutinib was associated with a higher major molecular response (MMR), deeper response, and shorter time to...

Ponatinib Increased Overall Survival in Patients with Chronic-Phase CML

A study published in Cancer found that treatment with ponatinib significantly improved overall survival (OS) for patients with chronic-phase chronic myeloid leukemia (CP-CML) and...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.